Jun 4, 2021 · Wegovy™ is the first and only once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist therapy approved for weight management for people living with obesity. The approval is based on the results from the STEP phase 3a clinical trial programme.

Bagsværd, Denmark, 22 May 2023 – Novo Nordisk today announced headline results from OASIS 1, a phase 3a trial in the global OASIS programme. OASIS 1 is a 68-week, efficacy and safety trial comparing once-daily oral semaglutide 50 mg for weight management to placebo in 667 adults with obesity or overweight with one or more comorbidities.

Sep 20, 2019 · Rybelsus ®, the brand name for oral semaglutide in the US, is the first approved glucagon-like peptide-1 (GLP-1) receptor agonist in a tablet. The approval of Rybelsus ® is based on the results from 10 PIONEER clinical trials which included 9,543 adults with type 2 diabetes.

Sources: Patient data is Novo Nordisk estimates; Value data: 2018 and 2021 data based on company reported sales for insulin, GLP-1, SGLT-2i and DPP-4i and IQVIA data for traditional OADs as of December 2018 and 2021

• Novo Nordisk continues to be the global market leader in the GLP-1 segment with a 54.8% value market share • Estimated global GLP-1 share of total diabetes

Novo Nordisk A/S Novo Alle 1 2880 Bagsværd Denmark +45-4444-8888 CVR-no. 24256790 Our medicines are for the approved indication for which they are authorised in the local country or region. For more information, please visit our product page

GLP-1 class expansion accelerates in the US in the first quarter of 2023 with volume growth across our portfolio NBRx: New-to-brand prescriptions; TRx: Total prescriptions; NN: Novo Nordisk; Scripts: Prescriptions; US: United States Note: Class growth calculated as Q1 2023 vs Q1 2022 Source: IQVIA Xponent, NBRx data from week ending 14 Apr 2023.

Our history spans a century and it all began with two small Danish companies, Nordisk Insulinlaboratorium and Novo Terapeutisk Laboratorium. After hearing of the discovery of insulin in 1921, Danish Nobel laureate August Krogh and …

• Novo Nordisk continues to be the global market leader in the GLP-1 segment with a 55.6% value market share • Estimated global GLP-1 share of total diabetes prescriptions

Jun 24, 2024 · Novo Nordisk announces 4.1 billion USD investment to expand US manufacturing capacity. In 2024, Novo Nordisk plans to boost its current investments, aiming to allocate USD 6.8 billion towards production, a significant increase from the …